---
document_datetime: 2025-06-18 14:01:54
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cinryze-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cinryze-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 15.2583205
conversion_datetime: 2025-12-27 16:14:22.688948
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cinryze

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                               |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0104              | Update of sections 4.6, 5.1 and 5.3 of the SmPC based on final results from the Icatibant Outcome Survey (IOS), listed as an imposed PASS in the Annex II. This is a prospective, observational disease registry. The Package Leaflet is updated accordingly. The RMP version 11.2 has also been submitted. In | 08/05/2025                          |                                             | SmPC, Annex II, Labelling and PL | SmPC new text Pregnancy Human C1-esterase inhibitor is a physiological component of human plasma. Therefore, no adverse effects on fertility, pre- and post-natal development are expected in humans. Animal-reproductive studies show no maternal or |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to bring the product information in line with the latest QRD template version 10.4 and to update Annex II of the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                           |            |     | embryofoetal effects in rats at dose levels up to 28 times the recommended human dose (1 000 IU) based on an average adult body weight of 70 kg. Data on a limited number of exposed pregnancies are available from clinical studies and from post-marketing experience (including data from two observational studies) and indicate no adverse effects of human C1-esterase inhibitor on pregnancy or on the health of the foetus/newborn child (see section 5.1). Cinryze should be given to pregnant women only if clearly indicated. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0103   | B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR                                                                                                                                                                                                                                                              | 10/09/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0102/G | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.II.d.2.a - Change in test procedure for the finished | 16/08/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | procedure                                                                                                                                                                                                                                      |            |     |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------------|
| IAIN/0101           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 14/05/2024 | n/a |             |                                   |
| IB/0100             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                 | 02/05/2024 |     | SmPC and PL |                                   |
| PSUSA/10104 /202306 | Periodic Safety Update EU Single assessment - human C1-esterase inhibitor                                                                                                                                                                      | 08/02/2024 | n/a |             | PRAC Recommendation - maintenance |
| IB/0099             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                  | 31/10/2023 | n/a |             |                                   |
| IB/0097/G           | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS               | 11/07/2023 | n/a |             |                                   |
| IAIN/0096           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 15/05/2023 | n/a |             |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0095           | A.3 - Administrative change - Change in name of the AS or of an excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 06/10/2022   | 09/10/2023   | SmPC, Labelling and PL   |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| IAIN/0094           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 13/07/2022   | n/a          |                          |                                   |
| T/0093              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15/03/2022   | 17/05/2022   | SmPC, Labelling and PL   |                                   |
| PSUSA/10104 /202106 | Periodic Safety Update EU Single assessment - human C1-esterase inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/02/2022   | n/a          |                          | PRAC Recommendation - maintenance |
| IAIN/0092/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 28/01/2022   | 17/05/2022   | Annex II and PL          |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0091 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/01/2022 | n/a |

<div style=\"page-break-after: always\"></div>

|             | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                      |            |     |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0089     | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                     | 02/12/2021 | n/a |
| IAIN/0088   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                   | 12/07/2021 | n/a |
| IAIN/0087/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 04/05/2021 | n/a |
| IAIN/0086   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                   | 23/02/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0082/G   | This was an application for a group of variations.                                                                                                                                                                                     | 18/02/2021   | 24/01/2022   | Annex II                         |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|
| IAIN/0085   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 01/02/2021   | 24/01/2022   | Annex II and PL                  |
| IB/0081     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                         | 13/10/2020   | 24/01/2022   | SmPC, Annex II, Labelling and PL |
| IA/0083     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                          | 08/10/2020   | n/a          |                                  |

<div style=\"page-break-after: always\"></div>

| IAIN/0080           | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                            | 25/09/2020   | n/a        |                 |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| IAIN/0079           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 24/07/2020   | n/a        |                 |                                   |
| IB/0078             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                         | 22/06/2020   | n/a        |                 |                                   |
| IAIN/0077           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 20/05/2020   | n/a        |                 |                                   |
| IAIN/0076           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing         | 23/03/2020   | 31/07/2020 | Annex II and PL |                                   |
| PSUSA/10104 /201906 | Periodic Safety Update EU Single assessment - human C1-esterase inhibitor                                                                                                                                                                      | 16/01/2020   | n/a        |                 | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0075   | B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20/12/2019   | n/a   |      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------|
| IAIN/0074 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 03/12/2019   | n/a   |      |
| II/0071/G | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 28/11/2019   | n/a   | site |

<div style=\"page-break-after: always\"></div>

|             | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect   |            |     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IAIN/0072/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/07/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|             | product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | of a medicinal   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------|
| II/0069     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/06/2019 | 31/07/2020 | SmPC and PL |                  |
| IAIN/0070/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 18/03/2019 | n/a        |             |                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0067/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 20/02/2019   | n/a   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
|             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished |              |       |

<div style=\"page-break-after: always\"></div>

| IB/0068   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                       | 30/01/2019   | n/a   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| II/0064   | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 17/01/2019   | n/a   |
| IA/0066   | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                       | 24/10/2018   | n/a   |
| IAIN/0063 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP   | 02/05/2018   | n/a   |
| IAIN/0062 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP   | 19/04/2018   | n/a   |
| IA/0061   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient     | 20/03/2018   | n/a   |

<div style=\"page-break-after: always\"></div>

| IAIN/0060           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                | 20/03/2018   | 27/08/2018   | Annex II and PL   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------|
| IAIN/0059           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                        | 16/03/2018   | n/a          |                   |                                   |
| II/0058/G           | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation | 15/03/2018   | n/a          |                   |                                   |
| PSUSA/10104 /201706 | Periodic Safety Update EU Single assessment - human C1-esterase inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/01/2018   | n/a          |                   | PRAC Recommendation - maintenance |
| IB/0057/G           | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS -                                                                                                                                                                                                                                                                                                                                                        | 09/11/2017   | n/a          |                   |                                   |

<div style=\"page-break-after: always\"></div>

|           | Tightening of in-process limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0056   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                 | 27/10/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0048   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                          | 14/09/2017 | 27/08/2018 | SmPC, Labelling and PL | The term Unit (U) is replaced by International Unit (IU) for the product potency throughout the product information. Historically assigned potency values were relative to an in- house reference standard whereby 1 Unit (U) is equal to the mean quantity of C1 inhibitor present in 1 ml of normal human plasma. An international reference standard (IU) has now been implemented where IU is also defined as the amount of C1 inhibitor present in 1 ml of normal human plasma. |
| IAIN/0054 | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                        | 23/06/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0053/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 01/06/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0052     | B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the properties of the FP                                                                                                                                                                                                                                           | 26/05/2017   | n/a   |                                 |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------------------|
| IA/0051     | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                | 15/05/2017   | n/a   |                                 |
| IB/0049/G   | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                               | 04/05/2017   | n/a   | Other variation                 |
| IAIN/0050/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - PMF when changes | 24/03/2017   | n/a   | Inclusion of an updated/amended |

<div style=\"page-break-after: always\"></div>

|                     | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0045             | Extension of Indication in children with hereditary angioedema (HAE) to include the treatment and pre- procedure prevention of angioedema attacks from 2 years and the routine prevention of angioedema attacks from 6 years; as a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 6.5 and 6.6 of the SmPC are updated. The key messages of educational materials in the Annex II, the Package Leaflet and the Labelling are updated in accordance. In addition, an update of regional information in module 3.2.R due to the proposed dose recommendation for children is submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 15/12/2016 | 26/01/2017 | SmPC, Labelling and PL | Please refer to the CHMP AR.      |
| PSUSA/10104 /201606 | Periodic Safety Update EU Single assessment - human C1-esterase inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/01/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0047/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                            | 20/10/2016 | 26/01/2017 | Annex II               |                                   |

<div style=\"page-break-after: always\"></div>

|           | intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0044   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21/06/2016 | n/a |
| IAIN/0043 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 01/06/2016 | n/a |

<div style=\"page-break-after: always\"></div>

| R/0040              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/04/2016   | 26/05/2016   | SmPC, Annex II, Labelling and PL   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------|
| IAIN/0042           | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                   | 29/04/2016   | n/a          |                                    |                                   |
| PSUSA/10104 /201506 | Periodic Safety Update EU Single assessment - human C1-esterase inhibitor                                                                                                                                                                                                                                                                                                                                                                                                        | 14/01/2016   | n/a          |                                    | PRAC Recommendation - maintenance |
| II/0039             | Early discontinuation of the Cinryze Registry Study 0624-401 and replacement by the Icatibant Outcome Survey (IOS), Disease Registry for compliance with an Annex II.D condition. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 17/12/2015   | n/a          |                                    |                                   |
| IG/0603/G           | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                         | 03/12/2015   | 26/05/2016   | SmPC, Annex II, Labelling and PL   |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0035   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other                                                                                                                                                                                                                                                                                                                                              | 06/11/2015   | n/a        |          | variation     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|---------------|
| IG/0621   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                                                                                                                              | 16/10/2015   | n/a        |          | PSMF location |
| IAIN/0038 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                             | 09/10/2015   | n/a        |          |               |
| IB/0032/G | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method | 27/07/2015   | 26/05/2016 | Annex II |               |
| IA/0034   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                   | 24/07/2015   | n/a        |          |               |
| IA/0033   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                             | 16/07/2015   | n/a        |          | procedure     |

<div style=\"page-break-after: always\"></div>

| IB/0030/G   | This was an application for a group of variations. B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure   | 30/04/2015   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IAIN/0031   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/04/2015   | n/a   |
| IAIN/0029   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/02/2015   | n/a   |

<div style=\"page-break-after: always\"></div>

|           | Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------|
| IB/0028/G | This was an application for a group of variations. B.II.e.1.b.z - Change in immediate packaging of the finished product - Type of container - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished | 14/01/2015 | n/a        |             |                                                                                                                                   |
| PSUV/0027 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/01/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                 |
| PSUV/0023 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/07/2014 | 30/09/2014 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0023. |
| IAIN/0025 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/07/2014 | n/a        |             |                                                                                                                                   |
| IAIN/0024 | B.V.a.1.d - PMF - Inclusion of a new, updated or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/06/2014 | n/a        |             |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------|
| IB/0022   | B.II.b.z - Change in manufacture of the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 01/06/2014 | n/a |                                                                                                    |
| IAIN/0021 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                       | 11/04/2014 | n/a |                                                                                                    |
| II/0017   | Submission of the final study report of study 0624- 203: 'an open-label single-dose study to evaluate the response and pharmacokinetics / pharmacodynamics of different doses of CINRYZE for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema' in order to fulfil the requirement of article 46 of the paediatric regulation. No change to the product information was required. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 20/03/2014 | n/a | Please refer to the scientific discussion Cinryze EMEA/H/C/001207/II/0017 for further information. |
| IB/0019   | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.                                                                                                                                                                                                                                                                                                                                                                         | 13/03/2014 | n/a |                                                                                                    |

<div style=\"page-break-after: always\"></div>

|             | duplication of line)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |                                   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0018/G   | This was an application for a group of variations. B.II.e.z - Change in container closure system of the Finished Product - Other variation B.IV.1.b - Change of a measuring or administration device - Deletion of a device                                                                                                                                                                                                                                                                                                                                                                                                      | 20/02/2014 | 30/09/2014 | SmPC, Labelling and PL |                                   |
| IAIN/0020/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 17/02/2014 | n/a        |                        |                                   |
| PSUV/0016   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/01/2014 | n/a        |                        | PRAC Recommendation - maintenance |
| II/0014     | Changes to Drug product specification to fulfill Annex II condition 002. Changes in the due date for conditions 003 and 004. B.II.d.z - Change in control of the Finished Product -                                                                                                                                                                                                                                                                                                                                                                                                                                              | 19/09/2013 | 30/09/2014 | SmPC, Annex II and PL  |                                   |

<div style=\"page-break-after: always\"></div>

|             | Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----|
| IAIN/0015   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/07/2013 | n/a |     |
| IAIN/0013/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of pharmacovigilance system | 19/03/2013 | n/a | the |
| IAIN/0012/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 06/03/2013 | n/a |     |

<div style=\"page-break-after: always\"></div>

|             | do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP   |            |            |                 |           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------|
| II/0011     | B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS                                                                                                             | 15/11/2012 | n/a        |                 |           |
| IB/0005     | B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised                                                                                                                                            | 09/11/2012 | n/a        |                 |           |
| II/0003     | To calibrate an in house concentrate standard against WHO 1 international standard for c1- inhibitor. This variation is to fulfil Annex II condition 001. B.II.z - Quality change - Finished product - Other                                                                            | 20/09/2012 | 25/10/2012 | Annex II        | variation |
| IAIN/0010   | B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                                                                                                                                                         | 14/09/2012 | 25/10/2012 | Annex II and PL |           |
| IAIN/0009/G | This was an application for a group of variations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the                                                                                                                                  | 22/08/2012 | n/a        |                 |           |

<div style=\"page-break-after: always\"></div>

|             | arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                        |            |            |                        | major contractual   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------|
| IA/0008     | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                                                                                                                                                                                                                                                                           | 17/08/2012 | n/a        |                        |                     |
| IB/0007     | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                | 17/08/2012 | 25/10/2012 | SmPC, Labelling and PL |                     |
| IAIN/0004/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes the properties of the FP | 12/07/2012 | n/a        |                        | do not affect       |

<div style=\"page-break-after: always\"></div>

| II/0001   | Amendment (timetable extension) of the conditions of the Marketing Authorisation B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                   | 19/04/2012   | 22/05/2012   | Annex II               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|
| IB/0002/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale A.6 - Administrative change - Change in ATC Code/ATC Vet Code | 14/04/2012   | 22/05/2012   | SmPC, Labelling and PL |